Biopharmaceutical company Coeptis Therapeutics Holdings Inc. closed a $4.3 million funding round led by CJC Investment Trust.
"We are grateful for the continued support from our investors, particularly in these transformative times for Coeptis Therapeutics," Dave Mehalick, Coeptis CEO, said in a prepared statement. "These individuals share our passion and long-term vision for Coeptis and their support goes beyond investment, reflecting a focus on the company's future."
Coeptis (NASDAQ: COEP) is developing cell therapy platforms for potential treatment of cancer and autoimmune and infectious diseases. Money raised from this round will "be allocated towards repayment of outstanding obligations, working capital and general corporate purposes." CJC Investment Trust is controlled by current board member Christopher Calise.
"This financing comes at an opportune moment as we are anticipating several near-term milestones," Mehalick said in a prepared statement. "The commitment from our investors not only strengthens our balance sheet but also bolsters our innovative cell therapy platforms and long-term growth prospects."
An earlier version of this story had an incorrect amount raised in the headline.
